Oncolys BioPharma Inc.(Code No. 4588; President & CEO: Yasuo Urata; “Oncolys”), a member of the Kobe Biomedical Innovation Cluster has confirmed, through experiments, the effectiveness of Novel Coronavirus Infection Drug OBP-2011 under development on COVID-19 variants. In joint research with a research group from the Joint Research Center for Human Retrovirus Infection (Kagoshima University Campus), Oncolys confirmed that OBP-2011 demonstrated activity on COVID-19 variants that may be resistant to vaccination, including the Brazil variant and the London variant, at the same level as on the wild type. Based on this result, it is expected that OBP-2011 can be used for the treatment of infected patients in an early phase, if a COVID-19 variant causes another pandemic in the future. At present, Oncolys is promoting a pre-clinical study and GMP-compliant production of investigational drugs for OBP-2011, aiming to start a clinical study in 2022. Oncolys also plan to implement a clinical study including patients who have tested positive for COVID-19 variants, based on this result.